Tectonic Therapeutic, Inc. (TECX) Form 8-K — Aug 6, 2026
Tectonic Therapeutic reported a second-quarter 2026 net loss of $22.3 million, or $1.18 per share, with research and development expense of $18.0 million and general and administrative expense of $6.2 million, both up modestly year over year on higher Phase 2 trial costs and stock compensation. The company completed enrollment of 191 patients across 14 countries in the TX45 APEX Phase 2 trial in pulmonary hypertension associated with HFpEF, and the Independent Data Monitoring Committee recommended the trial continue without modification after reviewing roughly 80% of expected patient exposure, with topline results expected early in Q1 2027.
Key figures
- Eps
- -$1.18 (Q2 2026 basic and diluted; vs -$1.07 in Q2 2025)
- Net Income
- -$22.3 million Q2 2026 net loss (vs -$20.0 million in Q2 2025)
- Total Assets
- $237.0 million
- Cash Position
- $227.1 million as of June 30, 2026
- Ga Expense
- $6.2 million Q2 2026 (vs $5.2 million Q2 2025)
- Cash Runway
- into Q1 2029
- Rnd Expense
- $18.0 million Q2 2026 (vs $17.2 million Q2 2025)
- Cash Dec312025
- $253.8 million
- Cash Mar312026
- $236.9 million
- Apex Enrollment
- 191 patients across 14 countries, including 137 with CpcPH and PVR>3 WU
- Working Capital
- $220.7 million
- Mean Baseline PVR
- 4.2 WU overall; 5.2 WU in CpcPH/PVR>3 WU subset
- Six Month Net Loss
- $47.5 million (vs $35.9 million in six months ended June 30, 2025)
- Atm Net Proceeds Q2
- $11.7 million
- Tx45 Topline Timing
- early Q1 2027
- Tx2100 Topline Timing
- by end of Q3 2026
- Weighted Avg Shares Q2
- 18964008
- Idmc Exposure Reviewed
- approximately 80% of expected patient exposure
Price after filing
Close on the filing date to close N calendar days later (from $29.17). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.